Plain-English translation of NCT05285891 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether people with early relapsing multiple sclerosis can safely stop taking after two years of treatment, or whether they need to keep taking it to stay well. Everyone in the study will first receive the medication for 24 months under standard medical care. Then, some people will continue the medication while others will switch to placebo (a dummy injection) to see what happens.
Multiple sclerosis medications can be powerful and helpful, but they also come with side effects and costs. Doctors want to know if some patients can safely take a break from this treatment once their disease is controlled, rather than continuing medication indefinitely.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly for screening, blood draws, physical and neurological exams, and MRI scans of your brain. For the first 2 years, everyone receives the active medication through IV infusions at months 0, 1, 6, 12, 18, and 24. At month 24, you will be randomly assigned to either keep receiving the medication or switch to placebo infusions every 6 months for another 2 years. Throughout the study, you'll have blood tests and stool samples collected to help researchers understand how the treatment affects your immune system.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
United States